Transgene SA (TRGNF)
USD 0.7
(0.0%)
USD 0.7
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 15.96 Million EUR | 1169.93% |
| 2022 | 1.25 Million EUR | -48.67% |
| 2021 | 2.44 Million EUR | -36.51% |
| 2020 | 3.85 Million EUR | -73.63% |
| 2019 | 14.62 Million EUR | -47.14% |
| 2018 | 27.66 Million EUR | -13.25% |
| 2017 | 31.89 Million EUR | -8.99% |
| 2016 | 35.04 Million EUR | 29.72% |
| 2015 | 27.01 Million EUR | -0.75% |
| 2014 | 27.21 Million EUR | 2.76% |
| 2013 | 26.48 Million EUR | -1.44% |
| 2012 | 26.87 Million EUR | 34.77% |
| 2011 | 19.93 Million EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2004 | 4.71 Million EUR | -6.72% |
| 2003 | 5.05 Million EUR | -8.72% |
| 2002 | 5.54 Million EUR | -5.96% |
| 2001 | 5.89 Million EUR | 0.39% |
| 2000 | 5.86 Million EUR | 7.59% |
| 1999 | 5.45 Million EUR | 42.33% |
| 1998 | 3.83 Million EUR | -5.27% |
| 1997 | 4.04 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 36.06 Million EUR | 126.15% |
| 2024 Q2 | 36.06 Million EUR | 0.0% |
| 2023 Q4 | 15.96 Million EUR | 0.0% |
| 2023 Q3 | 15.96 Million EUR | 17636.67% |
| 2023 Q1 | 11.57 Million EUR | 820.45% |
| 2023 Q2 | 90 Thousand EUR | -99.22% |
| 2023 FY | 15.96 Million EUR | 1169.93% |
| 2022 Q2 | 1.79 Million EUR | -88.1% |
| 2022 Q1 | 15.1 Million EUR | 516.9% |
| 2022 FY | 1.25 Million EUR | -48.67% |
| 2022 Q4 | 1.25 Million EUR | -89.8% |
| 2022 Q3 | 12.32 Million EUR | 585.6% |
| 2021 Q1 | 16.64 Million EUR | 331.58% |
| 2021 Q2 | 3.08 Million EUR | -81.46% |
| 2021 Q4 | 2.44 Million EUR | -83.93% |
| 2021 FY | 2.44 Million EUR | -36.51% |
| 2021 Q3 | 15.24 Million EUR | 393.72% |
| 2020 Q1 | 17.34 Million EUR | 18.58% |
| 2020 FY | 3.85 Million EUR | -73.63% |
| 2020 Q2 | 4.48 Million EUR | -74.14% |
| 2020 Q3 | 16.93 Million EUR | 277.66% |
| 2020 Q4 | 3.85 Million EUR | -77.23% |
| 2019 Q3 | 26.7 Million EUR | 28.79% |
| 2019 FY | 14.62 Million EUR | -47.14% |
| 2019 Q4 | 14.62 Million EUR | -45.23% |
| 2019 Q1 | 42.18 Million EUR | 52.46% |
| 2019 Q2 | 20.73 Million EUR | -50.85% |
| 2018 Q2 | 28.18 Million EUR | -42.16% |
| 2018 Q4 | 27.66 Million EUR | -42.8% |
| 2018 FY | 27.66 Million EUR | -13.25% |
| 2018 Q3 | 48.36 Million EUR | 71.62% |
| 2018 Q1 | 48.72 Million EUR | 52.79% |
| 2017 Q1 | 50.04 Million EUR | 42.81% |
| 2017 Q2 | 32.05 Million EUR | -35.95% |
| 2017 Q4 | 31.89 Million EUR | -38.34% |
| 2017 FY | 31.89 Million EUR | -8.99% |
| 2017 Q3 | 51.71 Million EUR | 61.35% |
| 2016 FY | 35.04 Million EUR | 29.72% |
| 2016 Q3 | 52.8 Million EUR | 48.95% |
| 2016 Q2 | 35.45 Million EUR | -33.32% |
| 2016 Q1 | 53.16 Million EUR | 96.83% |
| 2016 Q4 | 35.04 Million EUR | -33.64% |
| 2015 Q3 | 44.4 Million EUR | 62.81% |
| 2015 FY | 27.01 Million EUR | -0.75% |
| 2015 Q1 | 43.44 Million EUR | 59.62% |
| 2015 Q2 | 27.27 Million EUR | -37.22% |
| 2015 Q4 | 27.01 Million EUR | -39.16% |
| 2014 Q4 | 27.21 Million EUR | -37.0% |
| 2014 FY | 27.21 Million EUR | 2.76% |
| 2014 Q2 | 27.11 Million EUR | -36.32% |
| 2014 Q1 | 42.58 Million EUR | 60.78% |
| 2014 Q3 | 43.19 Million EUR | 59.31% |
| 2013 FY | 26.48 Million EUR | -1.44% |
| 2013 Q2 | 26.92 Million EUR | -29.33% |
| 2013 Q4 | 26.48 Million EUR | -35.07% |
| 2013 Q3 | 40.78 Million EUR | 51.48% |
| 2013 Q1 | 38.1 Million EUR | 41.79% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | 26.87 Million EUR | 0.0% |
| 2012 FY | 26.87 Million EUR | 34.77% |
| 2011 FY | 19.93 Million EUR | 0.0% |
| 2011 Q4 | 19.93 Million EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 Q2 | - EUR | 0.0% |
| 2004 Q4 | 4.71 Million EUR | 0.0% |
| 2004 Q2 | - EUR | 0.0% |
| 2004 Q1 | - EUR | -100.0% |
| 2004 FY | 4.71 Million EUR | -6.72% |
| 2003 FY | 5.05 Million EUR | -8.72% |
| 2003 Q3 | - EUR | 0.0% |
| 2003 Q4 | 5.05 Million EUR | 0.0% |
| 2003 Q1 | - EUR | -100.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2002 FY | 5.54 Million EUR | -5.96% |
| 2002 Q4 | 5.54 Million EUR | 0.0% |
| 2002 Q1 | - EUR | -100.0% |
| 2002 Q3 | - EUR | 0.0% |
| 2002 Q2 | - EUR | 0.0% |
| 2001 Q3 | - EUR | 0.0% |
| 2001 Q2 | - EUR | 0.0% |
| 2001 FY | 5.89 Million EUR | 0.39% |
| 2001 Q4 | 5.89 Million EUR | 0.0% |
| 2001 Q1 | - EUR | -100.0% |
| 2000 Q4 | 5.86 Million EUR | 0.0% |
| 2000 Q1 | - EUR | -100.0% |
| 2000 Q2 | - EUR | 0.0% |
| 2000 Q3 | - EUR | 0.0% |
| 2000 FY | 5.86 Million EUR | 7.59% |
| 1999 FY | 5.45 Million EUR | 42.33% |
| 1999 Q4 | 5.45 Million EUR | 0.0% |
| 1998 Q4 | 3.83 Million EUR | 0.0% |
| 1998 FY | 3.83 Million EUR | -5.27% |
| 1997 FY | 4.04 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -9621.385% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1199.537% |
| Evofem Biosciences, Inc. | 8000.00 USD | -199437.5% |
| GB Sciences, Inc. | 322 Thousand USD | -4857.453% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -9222.549% |
| Zenith Capital Corp. | 4456.00 USD | -358136.086% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -622.308% |
| CSL Limited | 11.23 Billion USD | 99.858% |
| CytoDyn Inc. | 141 Thousand USD | -11221.277% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 21.411% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -27121.104% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -10569.456% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -809.324% |
| SQZ Biotechnologies Company | 20.9 Million USD | 23.655% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -289504.499% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Mesoblast Limited | 100.29 Million USD | 84.084% |
| Marizyme, Inc. | 667.12 Thousand USD | -2292.791% |
| Genus plc | 228.2 Million USD | 93.005% |
| Pharming Group N.V. | 166.1 Million USD | 90.39% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -1037.83% |
| IMV Inc. | 27.39 Million USD | 41.738% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -194.169% |
| MultiCell Technologies, Inc. | 36.43 USD | -43818181.636% |
| ONE Bio Corp. | 592.19 Thousand USD | -2595.551% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 71.296% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -617.116% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -62997.356% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -740.836% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Enzolytics Inc. | - USD | -Infinity% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -3.966% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 287.12 Million USD | 94.44% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -12538.755% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -6861.896% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -93.163% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -2778.343% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -5909.374% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -10542.0% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -6849.772% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -1500181.955% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -10569.456% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 445 Thousand USD | -3487.191% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -19853.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -104.131% |
| SYBLEU INC | 300 Thousand USD | -5221.0% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -4225.442% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -95.865% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -3392.998% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -1274.935% |
| PureTech Health plc | 18.25 Million USD | 12.532% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -10542.0% |
| IXICO plc | 275 Thousand USD | -5704.727% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -34.834% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 39.325% |
| CSL Limited | 11.23 Billion USD | 99.858% |
| Cellectis S.A. | 36.21 Million USD | 55.917% |